Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011

Author:

Pfaller Michael A.12,Huband Michael D.1,Rhomberg Paul R.1,Flamm Robert K.1

Affiliation:

1. JMI Laboratories, North Liberty, Iowa, USA

2. University of Iowa, Iowa City, Iowa, USA

Abstract

ABSTRACT Omadacycline is a broad-spectrum aminomethylcycline in late-stage clinical development for the treatment of acute bacterial skin and skin structure infections and community-acquired pneumonia as an oral and an intravenous once-daily formulation. In this study, omadacycline and comparators were tested against 69,246 nonduplicate bacterial isolates collected prospectively during 2010 and 2011 from medical centers in Asia-Pacific (11,397 isolates), Europe (23,490 isolates), Latin America (8,038 isolates), and North America (26,321 isolates). Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A10 (2015) methods. A total of 99.9% of Staphylococcus aureus isolates were inhibited by ≤2 μg/ml of omadacycline (MIC 50/90 , 0.12/0.25 μg/ml), including 100.0% of methicillin-susceptible S. aureus isolates and 99.8% of methicillin-resistant S. aureus isolates. Omadacycline potencies were comparable for Streptococcus pneumoniae (MIC 50/90 , 0.06/0.06 μg/ml), viridans group streptococci (MIC 50/90 , 0.06/0.12 μg/ml), and beta-hemolytic streptococci (MIC 50/90 , 0.06/0.12 μg/ml) regardless of species and susceptibility to penicillin. Omadacycline was active against Enterobacteriaceae and was most active against Escherichia coli (MIC 50/90 , 0.5/2 μg/ml), Enterobacter aerogenes (MIC 50/90 , 2/4 μg/ml), Klebsiella oxytoca (MIC 50/90 , 1/4 μg/ml), and Citrobacter spp. (MIC 50/90 , 1/4 μg/ml). Omadacycline was active against Haemophilus influenzae (MIC 50/90 , 1/1 μg/ml) regardless of β-lactamase status and against Moraxella catarrhalis (MIC 50/90 , 0.12/0.25 μg/ml). The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be a concern.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference19 articles.

1. A One Health approach to antimicrobial resistance surveillance: is there a business case for it?

2. Centers for Disease Control and Prevention. 2014. Transatlantic Taskforce on Antimicrobial Resistance: progress report. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/drugresistance/pdf/tatfar-progress_report_2014.pdf.

3. The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria

4. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model

5. A new antibiotic kills pathogens without detectable resistance

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3